Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation

🥉 Top 5% JournalFeb 5, 2025Blood advances

Glucagon-like peptide 1 receptor agonists and risk of blood clots in veins among people with type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

In a cohort of 540,258 patients, the incidence of venous thromboembolism (VTE) was 6.1 events per 1000 patient-years for those receiving GLP1-receptor agonists compared to 7.6 events for those receiving DPP4 inhibitors.

GLP1-receptor agonist use is associated with a lower incidence of VTE in patients with type 2 diabetes mellitus compared to DPP4 inhibitors.
The hazard ratio for VTE with GLP1-RA was 0.78, indicating a potential reduction in risk.
For pulmonary embolism, the incidence was 2.9 events per 1000 patient-years in the GLP1-RA group versus 3.8 in the DPP4i group, with a hazard ratio of 0.74.
For deep vein thrombosis, GLP1-RA users had 3.9 events per 1000 patient-years compared to 4.7 events per 1000 patient-years in the DPP4i group, with a hazard ratio of 0.81.

AI simplified

Glucagon-like peptide 1 receptor agonists (GLP1-RA) are antidiabetic agents recently approved for weight loss. Obesity is an established risk factor for venous thromboembolism (VTE). Moreover, preclinical studies have shown that GLP1-RA may attenuate thromboxane-induced platelet activation. Therefore, we hypothesized that GLP1-RA use may reduce the risk of VTE. We performed a target trial emulation (TTE) using a population-based database of electronic health records to evaluate whether GLP1-RA use is associated with a reduction in VTE in patients with type 2 diabetes mellitus (T2DM) compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Patients who were newly initiated on GLP1-RA were propensity score matched to patients who were newly initiated on DPP4i. We evaluated the primary outcome, composite VTE, identified using ICD-10 (International Classification of Diseases, Tenth Revision) codes, within 12 months of the initiation of GLP1-RA or DPP4i. The study cohort comprised 540 258 patients with 270 129 individuals receiving either GLP1-RA or DPP4i. Over 12 months of follow-up, patients who received GLP1-RA had a lower incidence of VTE compared with patients who received DPP4i (6.1 vs 7.6 events per 1000 patient-years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.73-0.83). This was similar for pulmonary embolism (2.9 vs 3.8 events per 1000 patient-years; HR, 0.74; 95% CI, 0.68-0.82) and deep vein thrombosis (3.9 vs 4.7 events per 1000 patient-years; HR, 0.81; 95% CI, 0.75-0.88). In this propensity score-matched, TTE study, patients with T2DM who received a GLP1-RA had a lower risk of VTE at 1 year compared with patients who received DPP4i.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text ↗

Abstract

Full Text

Related papers